FGIN 1-27 is an indoleacetamide, a specific peripheral benzodiazepine receptor (PBR) ligand with Ki of 5.0 nM. FGIN 1-27 can cross the BBB (blood-brain barrier). FGIN 1-27 inhibits convulsive seizures caused by isoniazid.

Physicochemical Properties

Molecular Formula	C28H37N2OF
Molecular Weight	436.60458
Exact Mass	436.289
CAS #	142720-24-9
PubChem CID	132496
Appearance	Off-white to light yellow solid powder
Density	1.073g/cm3
Boiling Point	608.3ºC at 760mmHg
Flash Point	321.7ºC
Vapour Pressure	9.6E-15mmHg at 25°C
Index of Refraction	1.562
LogP	7.505
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	13
Heavy Atom Count	32
Complexity	522
Defined Atom Stereocenter Count	0
SMILES	FC1C=CC(C2=C(CC(N(CCCCCC)CCCCCC)=O)C3C(=CC=CC=3)N2)=CC=1
InChi Key	VUWXAQFLTSBUDB-UHFFFAOYSA-N
InChi Code	InChI=1S/C28H37FN2O/c1-3-5-7-11-19-31(20-12-8-6-4-2)27(32)21-25-24-13-9-10-14-26(24)30-28(25)22-15-17-23(29)18-16-22/h9-10,13-18,30H,3-8,11-12,19-21H2,1-2H3
Chemical Name	2-[2-(4-fluorophenyl)-1H-indol-3-yl]-N,N-dihexylacetamide
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

References	[1]. Development of ligands for the peripheral benzodiazepine receptor. Curr Med Chem. 2006;13(17):1991-2001.
Additional Infomation	2-[2-(4-fluorophenyl)-1H-indol-3-yl]-N,N-dihexylacetamide is a phenylindole.

Solubility Data

Solubility (In Vitro)

DMSO : ~100 mg/mL (~229.04 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (5.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (5.73 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (5.73 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.2904 mL	11.4521 mL	22.9043 mL
	5 mM	0.4581 mL	2.2904 mL	4.5809 mL
	10 mM	0.2290 mL	1.1452 mL	2.2904 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.